Contrast Induced Kidney Injury, Infamous Problem with No Magical Solutions

In patients at high risk of developing kidney complications undergoing angiography, we did not observe benefits when administering intravenous sodium bicarbonate vs. saline, or oral N-acetylcysteine vs. placebo, as to the prevention of death, dialysis or persistent deterioration of kidney function at 90 days, or the prevention of contrast induced kidney failure.

AngiographyMany small studies have looked into different strategies to prevent iodine contrast induced kidney injury with promising results, which have been recently unmasked by the NEJM publication of this large randomized controlled study testing two of the most popular strategies (sodium bicarbonate and N-acetylcysteine).

 

Intravenous sodium bicarbonate and acetylcysteine are widely used in the hope that they will prevent contrast induced kidney failure after angiography but there is no conclusive evidence as to its efficacy.

 

The present study used a 2×2 factorial design and randomized 5177 patients at high risk of kidney complications undergoing angiography to 1.26% sodium bicarbonate vs. 0.9% saline and 5 days of oral N-acetylcysteine vs placebo.


Read also: Peri-Procedural Infarction: More Frequent than and Not as Innocent as We Thought.


Primary end point was a composite of death, need of dialysis, persistent increase of at least 50% of baseline creatinine levels at 90 days. Contrast induced kidney failure was a secondary end point.

 

After interim analysis, the study was interrupted seeing that no interaction was found between interventions and primary end point (p=0.33), and therefore including more patients would not change outcomes.

 

Primary end point occurred in 4.4% of the sodium bicarbonate group vs 4.7% of patients receiving saline (OR 0.93, CI 0.72-1.22; p=0.62) and in 4.6% of patients receiving N-acetylcysteine vs 4.5% of patients receiving placebo (OR 1.02, IC 0.78 a 1.33; p=0.88).


Read also: TAVR in Patients with Classical Low Flow, Low Gradient.


There were no differences between the groups as regards contrast induced kidney injury.

 

Conclusion

Sodium bicarbonate and N-acetylcysteine do not reduce contrast induced kidney failure in patients at high risk of renal complications undergoing angiography.

Original title: Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. The PRESERVE Trial Group

Reference: S.D. Weisbord et al. N Engl J Med. 2018 Feb 15;378(7):603-614.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...